Disc Medicine Initiates Phase 1 Study of DISC-3405, Strengthening Position in Hematologic Disease Treatment

Disc Medicine, a clinical-stage biopharmaceutical company specializing in hematologic disease treatments, has announced the commencement of a Phase 1 study for its novel monoclonal antibody, DISC-3405 (formerly MWTX-003). The study will involve healthy volunteers and aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic activity of DISC-3405.

DISC-3405 is designed to target TMPRSS6, a protein involved in iron regulation, with the goal of increasing hepcidin production and reducing iron levels. The company believes that this approach may have therapeutic benefits in various diseases, including polycythemia vera and iron overload conditions.

John Quisel, President and CEO of Disc Medicine, expressed excitement about the initiation of the trial and highlighted the company’s position as leaders in hepcidin biology and iron homeostasis. He also mentioned plans to share data updates from ongoing clinical studies of their other programs later this year.

The Phase 1 trial will be a randomized, double-blind, placebo-controlled study, consisting of both single- and multiple-ascending dose portions. Following the completion of this study, Disc Medicine intends to pursue further trials in polycythemia vera, leveraging the Fast Track Designation received for DISC-3405.

DISC-3405, previously known as MWTX-003, was in-licensed from Mabwell Therapeutics in January 2023. Preclinical studies have shown promising results in animal models of beta-thalassemia and polycythemia vera, indicating its potential as a treatment for iron-overload conditions.

Disc Medicine is dedicated to discovering, developing, and commercializing innovative therapies for patients with serious hematologic diseases. Their focus on fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis, sets them apart in the field.

For more information about Disc Medicine and their pipeline of therapeutic candidates, visit www.discmedicine.com.

Please note that DISC-3405 is still an investigational agent and has not been approved for use as a therapy in any jurisdiction worldwide.